A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Brief description of study

If you have been diagnosed with colon or rectal cancer, you may qualify to participate in a study evaluating the combination of the drugs eflornithine and sulindac versus these drugs alone to treat your cancer.  The main goal of this phase III trial is to compare the effects of eflornithine and sulindac in combination for the treatment of colon and/or rectal cancers.  In addition, we would like to study blood samples to understand how much drug is in the blood over time, which is known as pharmacokinetic )PK) testing.

 


Clinical Study Identifier: s17-00109
ClinicalTrials.gov Identifier: NCT01349881
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.